5 results about "Small artery" patented technology

A pro-inflammatory and vasoconstrictor and endothelin-1 (ET-1) are pathogenic molecules related to a series of cardiovascular diseases. Unlike ET-1 signaling for vasoconstriction of the main artery, we have proven herein that coronary microvessels exhibit a unique signaling mechanism for constriction (independent of PKC, CPI-17, and intracellular calcium storage). The pathophysiological level of ET-1 acts preferentially on the microvessels to exert persistent vasoconstriction by activating Rho kinase upon binding to ETAR of the ET-1 receptor. The ETAR antagonist BQ123 only blocks but cannot reverse vasoconstriction against ET-1. In contrast, ROCK inhibitors (e.g., H-1152) are effective to reverse arteriolar systole against ET-1. Thus, ROCK inhibition is a potent and specific choice for the treatment of coronary ischemic disease (abnormal vasoconstriction) associated with microvascular dysfunction due to excessive production of ET-1. The ROCK inhibitors may also be used to treat microvascular diseases associated with diabetic retinopathy as well as microvascular dysfunction caused by cancer therapy or immunosuppressive drugs. Since H-1152 can also reduce the basal tension of microvessels, a ROCK inhibitor is also a good diagnostic agent when used during angiography or by a non-invasive method.

The invention discloses a cerebrovascular reactivity evaluation method for non-invasive calculation of a breath-holding index, and belongs to the field of hemodynamics numerical calculation and multi-scale modeling. The method comprises the following steps: constructing a one-dimensional (1D) arteriole hemodynamic model based on an allotactic scale law; constructing a main artery three-dimensional (3D) model, and coupling the main artery three-dimensional (3D) model with the arteriole one-dimensional model and the microcirculation zero-dimensional (0D) model to form a whole-brain 3D-1D-0D geometric multi-scale hemodynamic model; based on blood flow related data obtained in the experiment process, parameterization description is conducted on arteriole radius changes and microcirculation resistance changes; a breath holding index (BHI) is calculated by numerical solution of the geometric multi-scale model. According to the method, the non-invasive numerical calculation of the breath-holding index can be realized without directly implementing a breath-holding experiment or an external stimulation condition, and a stable and repeatable calculation means is provided for quantitative analysis and related engineering application of cerebrovascular hemodynamic behaviors.

The application discloses a blood pressure calculation method and equipment based on cross-scale fluid-solid coupling and considering nonlinear biomechanical characteristics of an aorta, and the method comprises the following steps: establishing a three-dimensional ideal aorta geometric model; establishing a zero-dimensional heart lumped parameter model to simulate the process that the heart pumps blood to the aorta inlet through periodic contraction and diastole; establishing a zero-dimensional three-element Windkessel model of small arteries to simulate blood flow microcirculation of peripheral small arteries; establishing a blood vessel wall biomechanical model containing residual stress of the aorta wall and active contraction of smooth muscle cells to obtain a pressure-radius relationship of the aorta wall as a fluid wall boundary condition to simulate the change process of the aorta radius in blood circulation; and coupling the three-dimensional ideal geometric model of the aorta, the zero-dimensional heart lumped parameter model and the zero-dimensional three-element Windkessel model to construct a cross-scale fluid-solid coupling system of hemodynamics, and the blood pressure in the aorta is calculated through iterative solution.

A method for evaluating the efficacy of cerartinib treatment for PAH in subjects suffering from PAH, and a method for increasing the ratio of distal pulmonary artery volume to proximal pulmonary artery volume (BV510ARatio) by administering an effective dose of cerartinib to the subject are also provided. A method for increasing the pulmonary vascular volume of small arteries and reducing hypertrophy of larger pulmonary artery vessels by administering an effective dose of cerartinib to subjects who require it is also provided.

The invention provides application of circular nucleic acid circMFN2 as well as a composition and a delivery method thereof in treatment of pulmonary arterial hypertension, and belongs to the technical field of nucleic acid drugs, the circMFN2 is formed by circling splicing of exons 3 and 4 of an MFN2 gene, the sequence is shown as SEQ ID NO: 1, the circMFN2 is remarkably reduced in a pulmonary arterial hypertension (PH) related sample, IGF2BP3 can be specifically combined, the stabilization effect of IGF2BP3 on PDK4 mRNA is blocked, and the circMFN2 can be used for treating the pulmonary arterial hypertension. Further, mitochondrial energy metabolism is recovered, and abnormal proliferation and migration of pulmonary artery smooth muscle cells are inhibited. The R8 modified circMFN2 liposome preparation disclosed by the invention can play a role in lung tissues after being administered by a nasal cavity, and can be used for remarkably improving indexes such as myelization / middle-layer thickening related to pulmonary arterial smooth muscles.